{"id":2534,"date":"2018-01-01T12:07:00","date_gmt":"2018-01-01T11:07:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2018\/der-arzneimittelbrief-jahrgang-2017"},"modified":"2018-01-01T12:07:00","modified_gmt":"2018-01-01T11:07:00","slug":"der-arzneimittelbrief-jahrgang-2017","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2018\/der-arzneimittelbrief-jahrgang-2017","title":{"rendered":"DER ARZNEIMITTELBRIEF Jahrgang 2017"},"content":{"rendered":"<p>Im vergangenen Jahr konnten Sie im 51. Jahrgang des ARZNEIMITTELBRIEFS insgesamt 90 Artikel lesen. Drei Hauptartikel sollen an dieser Stelle nochmals erw\u00e4hnt werden. Im Januar (1) besch\u00e4ftigten wir uns ausf\u00fchrlich mit neu zugelassenen onkologischen Wirkstoffen und kamen zu dem Schluss, dass bei der Mehrzahl der Onkologika die f\u00fcr Patienten relevanten Endpunkte, wie gesundheitsbezogene Lebensqualit\u00e4t und [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Im vergangenen Jahr konnten Sie im 51. Jahrgang des ARZNEIMITTELBRIEFS insgesamt 90 Artikel lesen. Drei Hauptartikel sollen an dieser Stelle nochmals erw\u00e4hnt werden. Im Januar (1) besch\u00e4ftigten wir uns ausf\u00fchrlich mit neu zugelassenen onkologischen Wirkstoffen und kamen zu dem Schluss, dass bei der Mehrzahl der Onkologika die f\u00fcr Patienten relevanten Endpunkte, wie gesundheitsbezogene Lebensqualit\u00e4t und [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[185,684,1518,137,255,1184,1280,2684,1983,1984,2873,1553,1185,155,1555,3065,1558,71,187,2354,1141,498,257,65,1557,4857,4858,83,1525,1526,1522,84,87,3116,3118,79,183,1552,1550,1551,1409,4833,181],"class_list":["post-2534","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-absolute-arrhythmie","tag-akutes-koronarsyndrom","tag-alirocumab","tag-antikoagulanzien","tag-arzneimittel","tag-arzneimittelbrief","tag-arzneimittelforschung","tag-arzneimittelstudien","tag-biologika","tag-biopharmazeutika","tag-biosimilars","tag-canagliflozin","tag-der-arzneimittelbrief","tag-diabetes-mellitus-typ-2","tag-empagliflozin","tag-evolocumab","tag-gliflozine","tag-herzinfarkt","tag-herzrhythmusstoerungen","tag-impfungen","tag-klinische-studien","tag-koronare-herzkrankheit","tag-medikamente","tag-myokardinfarkt","tag-natrium-glukose-cotransporter-2","tag-nocebo","tag-nozebo","tag-pci","tag-pcsk9","tag-pcsk9-antikoerper","tag-pcsk9-hemmer","tag-perkutane-koronarintervention","tag-perkutane-transluminale-koronare-angioplastie","tag-placebo","tag-plazebo","tag-ptca","tag-rhythmusstoerungen","tag-sglt2","tag-sglt2-hemmer","tag-sglt2-inhibitoren","tag-studien","tag-tripel-therapie","tag-vorhofflimmern"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2534","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2534"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2534\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2534"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2534"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}